abstract |
The present invention relates to antibody-drug conjugates (ADC) containing duocarmycin for use in the treatment of HER2-expressing human solid tumors and hematological malignancies, in particular breast cancer, gastric cancer, bladder cancer, cancer of the ovarian, lung cancer, prostate cancer, pancreatic cancer, colorectal cancer, squamous cell cancer of the head and neck or osteosarcoma and acute lymphoblastic leukemia; in particular, the present invention relates to ADCs containing duocarmycin for use in the treatment of human solid tumors with HER2 IHC 2+ or 1+ tissue status and negative for HER2 FISH; Advantageously, the present invention relates to ADCs containing duocarmycin for use in the treatment of triply negative breast cancer (TNBC). |